ACB Stock Chart & Stats
$2.67
$0.07(2.62%)
At close: 4:00 PM EDT
$2.67
$0.07(2.62%)
Day’s Range― - ―
52-Week Range$2.56 - $6.67
Previous Close$2.73
Volume1.41M
Average Volume (3M)1.17M
Market Cap
$193.19M
Enterprise Value$117.20
Total Cash (Recent Filing)$149.12M
Total Debt (Recent Filing)$22.68M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 11, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding64,861,820
10 Day Avg. Volume1,118,228
30 Day Avg. Volume1,168,832
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.81
P/FCF Ratio-7.20
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.19Price Target Upside57.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$206.02M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And LiquidityNearly $150M of cash and no debt provides durable financial flexibility: it reduces refinancing risk, funds working capital and capex while the business repairs profitability, and allows opportunistic M&A or investments without near-term capital markets dependence.
International Revenue Growth And Market LeadershipRapid international expansion shifts revenue away from a challenged Canadian market into higher-margin, regulated markets. Leadership positions in Germany, Poland and Australia create durable customer and distribution advantages and diversify regulatory and demand risk long-term.
EU‑GMP Capacity And Genetics-driven Production AdvantagesAn accretive EU‑GMP facility expands export-ready manufacturing capacity while genetics-driven yield gains materially lower unit costs. Together these structural operational improvements support sustainable margin expansion and scalable supply for international tenders and contracts.
Bears Say
Negative Free Cash FlowRecent FCF outflows show the business is not yet self-funding. Persistent negative cash generation can erode liquidity buffers over time, force external financing, and constrain reinvestment in production scale or marketing until consistent positive free cash flow is re-established.
Weak And Volatile ProfitabilityDeclining top-line and recurring operating losses indicate unstable earnings power. Volatility (from small profit to large loss) increases execution risk and undermines the durability of margins and long-term return on invested capital until revenue growth and cost structure prove sustainable.
Canadian Reimbursement Cut And Reduced Domestic DiversificationA structural 30% cut to Canadian medical reimbursement materially reduces domestic margins and cash flow. Concurrently exiting the Canadian consumer segment narrows revenue diversity, increasing reliance on international execution; both heighten downside if international demand or pricing softens.
Aurora Cannabis News
ACB FAQ
What was Aurora Cannabis (US)’s price range in the past 12 months?
Aurora Cannabis (US) lowest stock price was $2.56 and its highest was $6.67 in the past 12 months.
What is Aurora Cannabis (US)’s market cap?
Aurora Cannabis (US)’s market cap is $193.19M.
When is Aurora Cannabis (US)’s upcoming earnings report date?
Aurora Cannabis (US)’s upcoming earnings report date is Nov 11, 2026 which is in 92 days.
How were Aurora Cannabis (US)’s earnings last quarter?
Aurora Cannabis (US) released its earnings results on Aug 05, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.131 by $0.081.
Is Aurora Cannabis (US) overvalued?
According to Wall Street analysts Aurora Cannabis (US)’s price is currently Undervalued.
Does Aurora Cannabis (US) pay dividends?
Aurora Cannabis (US) does not currently pay dividends.
What is Aurora Cannabis (US)’s EPS estimate?
Aurora Cannabis (US)’s EPS estimate is -0.05.
How many shares outstanding does Aurora Cannabis (US) have?
Aurora Cannabis (US) has 64,861,820 shares outstanding.
What happened to Aurora Cannabis (US)’s price movement after its last earnings report?
Aurora Cannabis (US) reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.131. Following the earnings report the stock price went up 3.559%.
Which hedge fund is a major shareholder of Aurora Cannabis (US)?
Currently, no hedge funds are holding shares in ACB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurora Cannabis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.19 (57.00% Upside)
$4.19 (57.00% Upside)
Blogger Sentiment
Bullish
ACB Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $47.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.73%
Trailing 12-Months
Company Description
Aurora Cannabis (US)
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from facility engineering and design to genetic research, production, and the development of new products, all supported by extensive wholesale and retail networks. For medical users, Aurora offers diverse strains of dried cannabis, oils, capsules, and topical kits. Additionally, it markets a range of accessories, including vaporizers, consumable parts, herb mills (specifically for CanniMed products), grinders, and lockable vaporizer containers. The company is committed to advancing medical cannabis, with ongoing development across oral, topical, edible, and inhalable product categories. Aurora also provides key services such as patient counseling, design and construction assistance, and comprehensive analytical product testing for cannabis, alongside operating CanvasRX, a network dedicated to cannabis counseling and outreach. Its expansive brand family includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The corporate headquarters are located in Edmonton, Canada.
ACB Company Deck
ACB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: material short-term financial headwinds (notably a large year-over-year decline in adjusted EBITDA, lower adjusted net income, and negative free cash flow) driven largely by an external 30% reimbursement cut in Canadian medical. Offsetting these negatives are clear strategic strengths—17% international revenue growth to $43M, a 58% adjusted gross margin, strong cash position with no debt, an accretive EU GMP acquisition (Safari), genetics-driven production advantages (up to 40% yield improvement), and market leadership in several regulated international markets. Management frames FY2027 as a transitionary year with expected sequential improvement in Q2 and reiterated long-term targets (sustained double-digit growth and superior margins). Given the mix of significant near-term financial declines and pronounced strategic/operational positives, the overall tone is balanced.View all ACB earnings summariesACB Stock 12 Month Forecast
Average Price Target
$4.19
▲(57.00% Upside)
Technical Analysis
Ownership Overview
0.59% Insiders
0.07% Mutual Funds
0.41% Other Institutional Investors
95.53% Public Companies and
Individual Investors